Havens Advisors’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Havens Advisors’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10,000	Closed	-$231K	–	62
2020 Q4	$231K	Buy	+10,000	New	+$127K	0.22%	30

Havens Advisors's PRVL Position: Q1 2021 in Review

Havens Advisors sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 10,000 shares — an estimated $231K sold.

Havens Advisors first reported a position in PRVL in Q4 2020 and held it in 1 quarter. The position peaked at $231K in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

Havens Advisors reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Havens Advisors sold 10,000 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $231K.
Havens Advisors first reported a position in Prevail Therapeutics Inc. Common Stock in Q4 2020 and held it in 1 quarter.
Havens Advisors's Prevail Therapeutics Inc. Common Stock position peaked at $231K in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Havens Advisors's 13F filing for Q1 2021, filed 14 Apr 2021.